&nbsp;

Apr 2023

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Oct 2023

Drug

vanDETanib

Other Name(s): Caprelsa®

Quick Link(s):

Aug 2023

Drug

vemURAFenib

Other Name(s): Zelboraf ®

Quick Link(s):

Aug 2023

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

vismodegib

Other Name(s): Erivedge®

Quick Link(s):

Oct 2023

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

RITU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

VAND

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria

Drugs Used:

vanDETanib

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

VEMU

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria

Drugs Used:

vemURAFenib